M. Elisabeth· @ChildrenNeedUs_ · X·· 2026-04-20Score60
Reading
KRAS / RAS targeting: from platform to Phase 3
daraxonrasib ± GnP · mono ORR 47%; +GnP ORR 55%, DCR 90%
Body
Here’s a more compact & clear explanation of this study.
I woke up to multiple DM‘s(also disinformation about this data.)
#AACR26
#AACR2026
#PancreaticCancer
Heat 1 · 0 likes · 1 reply · 0 reposts
Source: M. Elisabeth · x.com